Kronos Bio公司削减了83%的劳动力,指定了新的临时首席执行官,并探索出售资产。 Kronos Bio cuts 83% of its workforce, names new interim CEO, and explores selling assets.

Kronos Bio是一家生物制药公司,正在改组其领导层,将劳动力裁减83%。 Kronos Bio, a biopharmaceutical firm, is reshuffling its leadership and cutting its workforce by 83%. Deborah Knobelman将从12月3日起成为新总裁和临时首席执行官,而现任首席执行官Norbert Biscofberger将离职,但留在董事会。 Deborah Knobelman will become the new President and Interim CEO starting December 3, while current CEO Norbert Bischofberger will leave his role but stay on the Board. 该公司正在探索各种选择,例如企业组合或出售其临床前资产,以提高股东的价值。 The company is exploring options like business combinations or selling its preclinical assets to improve value for shareholders.